Fenofibrate/simvastatin fixed dose combination is useful for patients with mixed dyslipidemia, but rarely produce myopathy like myalgia, myositis or rhabdomyolysis. We report the case of fenofibrate/simvastatin fixed dose combination induced rhabdomyolytic acute renal failure and poor glucose control in a 69-year old female, a known case of type-2 diabetes mellitus and with a history of acute coronay syndrome and cerebal infarction. She was on antihypertensive, oral hypoglycemic and antiplatelet medications with fenofibrate/simvastatin fixed dose combination. She was admitted with high blood glucose, vomiting, muscle weakness and decreased urine output and had raised serum creatinine, creatinine phosphokinase and myoglobin. After ruling out all other causation for rhabdomyolysis, we stopped fenofibrate/simvastatin fixed dose combination and started supportive management. Patient showed gradual recovery in renal function and motor weakness. Her glucose is gradually well controlled. Patient was discharged with good urine output and on antihypertensive, hypoglycemic drug and insulin and diet restrictions for lipid control. Thus, prompt diagnosis of rhabdomyolysis due to fenofibrate/ simvastatin fixed dose combination in absence of other aetiology and the multidisciplinary management can prevent further complication with favorable outcome.